Acknowledgements and Disclosures

The INBUILD trial was funded by Boehringer Ingelheim International GmbH (BI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for the development of this poster. Editorial support and formatting assistance was provided by Melanie Stephens and Wendy Morris of FleishmanHillard Fishburn, London, UK, which was contracted and funded by BI. BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations.

Claudia Valenzuela reports personal fees from Boehringer Ingelheim, Hoffmann-La Roche, and Galapagos. Vincent Cottin reports research grants, personal fees, and non-financial support from Boehringer Ingelheim and Roche; personal fees from Bayer/Merck Sharp & Dohme, Celgene, Galapagos, Galecto, Gilead, Novartis, Promedior, and Sanofi; and personal fees and non-financial support from Actelion.